Orion Group Interim Report January–March 2025
ORION CORPORATION
INTERIM REPORT 1–3/2025
23 APRIL 2025 at 12:00 EEST
Orion Group Interim Report January–March 2025
January–March 2025 Highlights
- Net sales totalled EUR 354.6 (January–March 2024: 308.5) million
- Operating profit was EUR 77.9 (56.0) million
- Basic earnings per share were EUR 0.44 (0.31)
- Cash flow from operating activities per share was EUR 0.55 (0.78)
- Outlook for 2025 remains unchanged: Net sales are estimated to be EUR 1,550 million to EUR 1,650 million. Operating profit is estimated to be EUR 350 million to EUR 450 million.
Key figures
| 1–3/25 | 1–3/24 | Change % | 1–12/24 | |
| Net sales, EUR million | 354.6 | 308.5 | +14.9% | 1,542.4 |
| EBITDA, EUR million | 91.5 | 68.5 | +33.6% | 509.4 |
| % of net sales | 25.8% | 22.2% | 33.0% | |
| Operating profit, EUR million | 77.9 | 56.0 | +39.1% | 416.6 |
| % of net sales | 22.0% | 18.2% | 27.0% | |
| Profit before taxes, EUR million | 76.8 | 54.9 | +39.9% | 413.1 |
| % of net sales | 21.7% | 17.8% | 26.8% | |
| Profit for the period, EUR million | 61.3 | 43.8 | +39.9% | 329.9 |
| % of net sales | 17.3% | 14.2% | 21.4% | |
| Research and development expenses, EUR million | 41.0 | 36.8 | +11.3% | 179.6 |
| % of net sales | 11.6% | 11.9% | 11.6% | |
| Capital expenditure, EUR million | 20.5 | 13.1 | +56.7% | 86.1 |
| % of net sales | 5.8% | 4.2% | 5.6% | |
| Interest-bearing net liabilities, EUR million | 61.8 | 6.4 | > 100 % | 121.7 |
| Basic earnings per share, EUR | 0.44 | 0.31 | +39.8% | 2.35 |
| Cash flow from operating activities per share, EUR | 0.55 | 0.78 | -29.7% | 2.09 |
| Equity ratio, % | 62.9% | 48.8% | 61.9% | |
| Gearing, % | 5.8% | 0.9% | 12.1% | |
| Return on capital employed (before taxes), % | 23.4% | 22.8% | 34.9% | |
| Return on equity (after taxes), % | 23.7% | 21.9% | 34.8% | |
| Average number of personnel during the period | 3,928 | 3,673 | +7.0% | 3,712 |
President and CEO Liisa Hurme:
Strong start for the year
“In January–March 2025, our net sales increased by 14.9 percent to EUR 354.6 (308.5) million and operating profit increased by 39.1 percent to EUR 77.9 (56.0) million.
The year 2025 has started strongly with almost all business divisions reporting good growth. Nubeqa® continued to drive the growth of the Group and the Innovative Medicines business division. Both royalty income and product sales increased significantly from the comparison period. In addition, Nubeqa®’s product sales grew from the previous quarter and were at an all-time high so far.
In Branded Products, all therapy areas grew nicely. Starting from this reporting period, we will split the division’s net sales by three therapeutic areas. Each therapy area’s strategy is to build business around one key product group. In Respiratory, the key product group is Easyhaler® product portfolio, in CNS entacapone products and in Women’s Health Divina® series.
Generics and Consumer Health and Animal Health business divisions also continued their growth path as expected in the first quarter of 2025. The decline in Fermion’s external net sales from the comparison period is explained by the allocation of capacity more to internal use, as well as by timing of deliveries.
Operating profit grew again significantly faster than net sales, which is mostly explained by the growth of Nubeqa® royalties and product sales, but also by the good development of the rest of the business. The growth of Nubeqa® royalties was strong, especially considering the fact that, as usual, the previous quarter’s product sales, which were very good at the end of 2024, have been deducted from the royalty. Operating expenses increased but were lower than we anticipated. Sales and marketing expenses were increased by, among other things, investments in the promotion of the Easyhaler® product portfolio, as well as the Japanese sales office established last year. The increase in research and development costs is explained by the progress of clinical development projects and the research portfolio, where the costs of biological medicines, in particular, increase significantly as they approach the clinical development stage.
US import tariffs continue to be a hot topic worldwide, and there is a lot of uncertainty around the topic right now. The United States is an important market for Orion, and we will, of course, follow the development of the situation closely.
In March, we announced that Orion is establishing a new research & development centre in Cambridge, UK during 2025. With this we aim to accelerate our global growth strategy and the development of innovative medicines. The new centre will focus on the pharmaceutical development of new biological and large-molecule therapies.
Orion’s own clinical development projects progressed as planned during the early part of the year. In addition, we have added to Orion’s list of key clinical development projects a Phase 3 project, in which our partner Tenax develops oral levosimendan for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction. Tenax has announced that it will increase the number of patients in the ongoing study and plans to start during 2025 a second phase III study which is aiming for global registration. With these advances, we felt the time was right to include Tenax Phase III projects with levosimendan in Orion’s research pipeline. The original license agreement with Tenax (formerly Phyxius) was signed already in 2013.
All in all, the year 2025 has started very well and from here it is good to continue this year forward together with all Orionees and numerous partners.”
Outlook for 2025
Net sales are estimated to be EUR 1,550 million to EUR 1,650 million.
Operating profit is estimated to be EUR 350 million to EUR 450 million.
Webcast and Conference Call
A webcast and a conference call for analysts, investors and media representatives will be held on Wednesday, 23 April 2025 at 13.30 EEST.
A link to the live webcast is available on Orion’s website at www.orionpharma.com/investors. A recording of the event will be available on the website later the same day.
Conference call can be joined by registering through the following link:
https://palvelu.flik.fi/teleconference/?id=50050278
Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.
Questions can also be presented in writing through the question form of the webcast.
Upcoming events
| Capital Markets Day 2025 | Thursday 22 May 2025 |
| Half-Year Financial Report January–June 2025 | Friday 18 July 2025 |
| Interim Report January–September 2025 | Tuesday 28 October 2025 |
Espoo, 23 April 2025
Board of Directors of Orion Corporation
For additional information about the report:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721 or +358 50 966 2721
Publisher:
Orion Corporation
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion’s net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion’s A and B shares are listed on Nasdaq Helsinki.
Attachment
